Zimmerman and colleagues in Brazil studied the persistence of cognitive damage in mice with documented cerebral malaria after cure of the acute parasitic disease with chloroquine, an antimalarial drug therapy by administering a battery of behavioral tests to these mice determined postdoctoral researcher Patricia Rice that in in memory performance was still present 30 days after initial infection with malaria Cognitive deficits that persist for years after the episode of cerebral malaria in 11 % to 28 % of children reported to survive the infection what to choose . Has been used both desferoxamine and N-acetylcysteine, in order diseases in humans and diseases in humans and their side effects are known. The study authors suggest that these antioxidant drugs should be studied as additive therapy for malaria drugs in clinical trials their potential its potential to reduce or prevent cognitive damage after cerebral malaria. ‘Our findings are exciting because the clinical effects limited limited to cerebral malaria,’says Zimmerman. ‘Oxidative stress is considered be an important mechanism in brain injury in other types of severe infection and in chronic non-infectious diseases such as neurodegenerative diseases. Antioxidant treatment may be a successful therapeutic strategy for controlling long-lasting neurological consequences in these conditions, as well. Neurobiologists new study comes from a long-term collaboration between Zimmerman and Dr. Hugo Castro – Faria – Neto and his group at the Oswaldo Cruz Foundation, a large Brazilian Institute for the Study, Prevention and Treatment of Infectious Diseases The Brazilian research team also included. Neurobiologist Jo? O Quevedo and staff at the University Extremo Sul Catarinense in Santa Catarina, Brazil.

– Supportive study shows separation of placebo at 5 and 10 mg cans. Drug-drug interaction proof of concept trial statistical significance all doses tested.

As announced tabling Lu AA21004 The expanded in 2012. The expanded Phase III the program of Lu AA21004 based on clinical information were obtained yet. The available evidence indicates encouraging results for the potential efficacy and safety of Lu AA21004:.